{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T11:10:05Z","timestamp":1748689805828,"version":"3.41.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.clinthera.2015.10.009","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T16:45:20Z","timestamp":1447173920000},"page":"212-215","source":"Crossref","is-referenced-by-count":5,"title":["Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis"],"prefix":"10.1016","volume":"38","author":[{"given":"Ali Reza","family":"Salili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roswitha","family":"Skendaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas W.","family":"Jehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne B.","family":"Taegtmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.10.009_bib1","unstructured":"Transtec\u00ae [product information]. Gr\u00fcnenthal Pharma AG, Glarus S\u00fcd, Switzerland, 2009"},{"key":"10.1016\/j.clinthera.2015.10.009_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis","year":"2012","journal-title":"J Support Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2015.10.009_bib3","doi-asserted-by":"crossref","first-page":"s17","DOI":"10.1191\/0269216306pm1127oa","article-title":"Renal impairment: a challenge for opioid treatment? The role of buprenorphine","volume":"20","author":"B\u00f6ger","year":"2006","journal-title":"Palliat Med"},{"key":"10.1016\/j.clinthera.2015.10.009_bib4","first-page":"5","article-title":"The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice","volume":"21","author":"Murtagh","year":"2007","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.clinthera.2015.10.009_bib5","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.clinthera.2015.10.009_bib6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.clinthera.2015.10.009_bib7","doi-asserted-by":"crossref","first-page":"S661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.10.009_bib8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/bja\/64.3.276","article-title":"Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites","volume":"64","author":"Hand","year":"1990","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clinthera.2015.10.009_bib9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ejpain.2005.12.001","article-title":"Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine","volume":"10","author":"Filitz","year":"2006","journal-title":"Eur J Pain"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815011704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815011704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T10:57:00Z","timestamp":1748689020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815011704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0149291815011704"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.10.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}